Tzield Approval Expands to Younger Patients
First disease-modifying option available for children as young as 1 year with stage 2 type 1 diabetes
By
Kathryn Wighton
April 22, 2026
Clinical Scorecard: Tzield Approval Expands to Younger Patients
At a Glance
Category Detail
Condition Type 1 Diabetes (T1D) Key Mechanisms CD3-directed monoclonal antibody targeting to delay disease progression Target Population Pediatric patients aged 1 year and older with stage 2 T1D Care Setting Outpatient, pediatric care
Key Highlights
FDA approved teplizumab-mzwv (Tzield) for younger pediatric patients Indicated for delaying onset of stage 3 T1D in patients aged 1 year and older Approval based on PETITE-T1D Phase 4 study data Previously approved for patients aged 8 years and older Teplizumab received breakthrough therapy and orphan drug designations Guideline-Based Recommendations
Diagnosis
Diagnosis of stage 2 T1D requires presence of at least two diabetes-related autoantibodies and dysglycemia. Management
Administer teplizumab intravenously once daily for 14 consecutive days. Monitoring & Follow-up
Follow-up for up to 26 months post-treatment to assess safety and efficacy. Risks
Potential for adverse effects related to immunomodulation. Patient & Prescribing Data
Children younger than 8 years with stage 2 T1D
Effective in delaying the onset of stage 3 T1D.
Clinical Best Practices
Ensure proper diagnosis of stage 2 T1D before treatment initiation. Monitor patients closely for signs of progression to stage 3 T1D. Educate families on the importance of follow-up and management of T1D. Related Resources & Content
